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Abstract 
The endocannabinoid system is a modulatory system that has been strongly associated with the regulation of 
functions as learning and memory, pain perception and sensory physiology in many areas of the central nervous 
system. However, although a role in sensory processing has been demonstrated at the level of the thalamus, the 
influence of the endocannabinoid system on thalamic rhythms and oscillations has been less studied, despite the fact 
that such activities are significant characteristics of the thalamic state. 
The present work aimed to characterize the role of anandamide (AEA) – one of the endogenous CB1 receptor 
agonists – and AM251 – a CB1 antagonist – in the modulation of burst firing and oscillatory activity present in the 
dLGN of the anesthetized rat. Administration of AEA (0.5 mg/kg iv) increased the number of bursts in the majority 
of the cells tested and induced the appearance of a slow delta-like (1.5 Hz) oscillatory activity. These effects were 
CB1-mediated, as demonstrated by the complete antagonism during the co-application of AM251 (0.5 mg/kg iv). 
Thus, by demonstrating that the AEA-mediated activation of CB1 receptors increases spontaneous bursting and 
oscillatory activity in the thalamus our study infers that endocannabinoids could have a role in processes controlling 
the sleep–wake cycle and level of arousal. 
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Introduction 
The endocannabinoid anandamide (AEA) is an arachidonic acid derivative (Devane et al., 
1992 and Mechoulam et al., 1995) which acts via two families of G-protein-coupled receptors, CB1 and 
CB2 (Matsuda et al., 1990 and Munro et al., 1993). As a fatty acid component of membrane 
phospholipids (Di Marzo et al., 1994) AEA is synthesized and released on demand following a 
depolarization-induced increase in the intracellular concentration of calcium (Sugiura et al., 1996), which 
is mainly triggered by the activation of group I metabotropic glutamate receptor (mGluR) and muscarinic 
acetylcholine receptor (mAChR) receptors (Maejima et al., 2001 and Kim et al., 2002). 
The best described action of AEA is the retrograde modulation of neurotransmitter release by an 
action on presynaptic CB1 receptors (Freund et al., 2003). This has been described mainly in the 
hippocampus and cerebellum, where AEA has been shown to inhibit both GABAergic and glutamatergic 
neurotransmission (Schlicker and Kathmann, 2001 and Piomelli, 2003). However, the activation of CB1 
receptors by AEA can also increase the release of glutamate (Glu) and acetylcholine (ACh) in the cerebral 
cortex and hippocampus (Acquas et al., 2000 and Ferraro et al., 2001). 
In the somatosensory thalamus, Sun et al. (2011) have recently demonstrated the presence of high 
levels of CB1 receptors and suggested a role in regulating both inhibitory synapses within the thalamic 
reticular nucleus (TRN) and excitatory synapses between cortex and thalamus. These results that suggest 
CB1 receptors are in a unique position to modulate sensory transmission and oscillatory activity within 
the thalamocorticothalamic circuit. In addition, we have previously demonstrated that application of both 
locally and systemically applied cannabinoid agents can alter the firing rates of individual visual thalamic 
cells in the rat, both during driven and spontaneous activities (Dasilva et al., 2012) clearly dividing the 
population into cells excited and inhibited by cannabinoid activation. In that study, we noted that the level 
of spontaneous activity appeared to be a factor in the polarity of the effect of exogenous cannabinoids, 
such that cells excited by the drugs had significantly lower spontaneous activity than those inhibited. 
An obvious extension to these studies is to consider how cannabinoids may affect cells interacting as 
populations, influencing synchronous and rhythmic firing since (i) rhythms are a fundamental part of 
thalamic activity, (ii) rhythms are mediated at the level of the thalamus by ACh, GABA and Glu, 
neurotransmitters highly modulated by the endocannabinoid system (Ferraro et al., 2001 and Schlicker 
and Kathmann, 2001), and (iii) a role for the endocannabinoid system in regulating neuronal rhythmicity 
and synchrony has been previously described (Hájos et al., 2000, Willinsky et al., 1975, Buonamici et al., 
1982, Consroe et al., 1997, Ilan et al., 2004, Robbe et al., 2006, Hajós et al., 2008, Morgan et al., 2008, 
Mason and Cheer, 2009, Sun et al., 2011 and Sales-Carbonell et al., 2013). 
Thalamic neurons show oscillatory activity in a broad range of frequencies ranging from slow 
oscillations (0.1–1 Hz) during deep non-paradoxical sleep, to gamma oscillations (30–80 Hz) during 
awareness (Steriade et al., 1993). Further, thalamic cells fire action potentials in two different patterns: (i) 
tonic spikes and (ii) spikes in burst. Bursts include those spikes that crown a calcium action potential 
generated by the activation of a low-threshold calcium current preceded by a hyperpolarized state 
(Jahnsen and Llinás, 1984 and Lu et al., 1992), and have been classically associated to sleep-like states 
(Livingstone and Hubel, 1981 and Steriade et al., 1993). 
Here we examine the effects of systemically applied AEA and AM251 –a CB1 receptor agonist and 
antagonist, respectively– focussing on two important and related aspects of thalamic function – the 
rhythmic firing pattern found when thalamic cells fire in burst mode and sleep-like oscillatory activity 
(Steriade et al., 1993). 
Experimental procedures 
Animals and preparation 
Experiments were carried out in six Lister-hooded adult rats weighing between 250 and 350 g. All 
procedures complied with the ethical use of animals specified in the European Communities Council 
Directive of November 24, 1986 (86/609/EEC) and Animals (Scientific Procedures) Act 1986, UK Home 
Office. 
Anesthesia was induced with a mixture of ketamine (50 mg kg−1, Ketolar, Parke-Davis, Madrid, 
Spain) and xylazine (10 mg kg−1, Sigma–Aldrich, Madrid, Spain) given intra-peritoneally, while an 
intravenous mixture of ketamine (13 mg kg−1 h−1) and xylazine (1.5 mg kg−1 h−1) in glucose saline was 
supplied through the lateral tail vein for surgery and maintenance via an infusion pump (Harvard 
Apparatus). 
The ECG was continuously observed (Biopac Systems Inc., CA, USA) and maintained within normal 
physiological limits to ensure an appropriate level of anesthesia. Body temperature was also continuously 
measured and kept around 37 ± 0.5 °C using a thermal blanket (Harvard Apparatus Homeothermic 
Blanket). Lidocaine gel was applied to pressure points. 
Animals were placed in a customized stereotaxic apparatus such that the head was secured in a 
horizontal orientation and the entire right visual hemifield was unobstructed. To access the dorsal lateral 
geniculate nucleus (dLGN), the skull was exposed, a craniotomy was drilled 4.5 mm posterior to bregma 
and 3.5 mm lateral to the midline (Paxinos and Watson, 2007), and the dura mater was retracted with a 
curved needle. After experiments animals were killed with an anesthetic overdose without recovering 
from anesthesia. 
Recording of single neuronal activity and electrocorticographic (ECoG) 
A hydraulic microelectrode multidrive of eight channels (tungsten electrodes, 1.0 MΩ, FHC Inc., ME, 
USA) was used to record simultaneously the extracellular activity of groups of dLGN neurons during 
spontaneous, undriven activity. To locate the dLGN, the multidrive was positioned over the craniotomy 
and each single microelectrode was advanced into the brain while stimulating the appropriate eye with 
hand-held stimuli. After reaching the dLGN, extracellular single-cell neural signals with a good signal-to-
noise ratio were isolated and continuously monitored using a 310 Tektronix Oscilloscope (Tektronix 
Holland N.V., Heerenveen, The Netherlands) and an audio monitor (FHC Inc.). These signals were 
preamplified (Preamplifier board, Plexon Inc., TX, USA) and fed into a multichannel acquisition 
processor (Plexon, Inc.) that allowed the amplification, filtering and real-time spike sorting of the 
acquired signals, which were stored in a computer provided with RASPUTIN software (Real-time 
Acquisition System Programs for Unit Timing in Neuroscience, Plexon Inc.). Off-line analyses were 
carried out using Offline Sorter and Neuroexplorer softwares (Plexon Inc.), MS Excel (Microsoft 
Corporation), MATLAB (The MathWorks Inc., MA, USA) and SPSS (SPSS Inc., NY, USA). ECoG 
activity was recorded by means of a parallel bipolar microelectrode (FHC Inc.) positioned in the left 
visual cortex. Activity was filtered (0.1 Hz–1 kHz) and preamplified using a differential AC amplifier (A-
M Systems, WA, USA) and fed into a continuous channel of a multichannel acquisition processor (Plexon 
Inc.). Offline analysis was carried out using Neuroexplorer software (Plexon Inc.). 
Pharmacology 
AEA (N-(2-hydroxyethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide) and AM251 (N-(piperidin-1-yl)-5-(4-
iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide) were obtained from Tocris 
(Bristol, United Kingdom). Both were dissolved in vehicle (1:1:18 cremophor/ethanol/saline) and applied 
intravenously via the lateral tail vein using the same concentration (0.5 mg/kg) and protocol described in 
our previous work (Dasilva et al., 2012). Once dLGN cells were isolated, spontaneous activity was 
recorded in control conditions for at least 5 min after which AEA was injected and neuronal activity 
recorded for a further 10–15 min to determine the period of maximal effect and recovery. In the 
experiments where AM251 was used we waited 5 min after AM251 injection before administration of 
AEA. 
Data analysis 
Drug-induced changes were measured by averaging the firing rate over a time window of 5 min at the 
time of maximal effect after drug administration and comparing this to that obtained using the same 
duration of time window during the control, pre-drug period. Only those effects where p < 0.05 were 
considered significant (one-way analysis of variance (ANOVA) or Friedman tests followed by Dunnett t-
test or Wilcoxon signed rank test when appropriate). Population data were analyzed using a one-way 
ANOVA, Friedman test, paired Student t-test, Mann–Whitney test or Wilcoxon signed rank test, where 
appropriate. When necessary, post hoc comparisons were made. Burst analysis was carried out using 
Matlab software (The MathWorks Inc.). The criteria for considering a train of action potentials as a burst 
was the presence of two or more spikes with a preceding silent period of at least 50 ms and an interspike 
interval not greater than 4 ms ( Guido et al., 1992; Lu et al., 1992). Action potentials not fulfilling this 
criterion were considered as tonic firing. The calculation of the number of bursts was achieved by 
counting how many bursts were within a period of interest, and the percentage of spikes in bursts was 
defined as the ratio of the number of spikes within bursts to the total number of spikes within that period. 
Autocorrelogram and power spectral density (PSD) analyses were carried out using Neuroexplorer 
software (Plexon Inc.). An autocorrelogram can be defined as a cross-correlogram of a neuronal signal 
with itself indicating similarities in the firing pattern as a function of time. Thus, in this study, 
autocorrelograms were used to indicate periodicities and harmonic frequencies in the firing of neurons 
across a ± 2-s time window. The PSDs for individual neurons were calculated across the same 5-min time 
windows described above. The PSDs of the electrocorticograms were calculated in the same way as for 
individual neurons, but continuous values in millivolts were used instead of a rate histogram. 
Results 
We report the effect of AEA application on 84 neurons in the dLGN of six rats. Up to eight cells were 
recorded simultaneously, and their activity was studied both in control conditions and during the systemic 
iv administration of the CB1 receptor agonist AEA (0.5 mg/kg) and the CB1 antagonist AM251 
(0.5 mg/kg). 
CB1 receptor activation alters the spontaneous bursting activity of dLGN relay neurons 
Administration of AEA had a significant effect on the number of bursts compared to the control values 
(Student t-test, p < 0.001, N = 84). Post-hoc observation showed that the administration of AEA increased 
the number of bursts in 70% (59/84) of our population of neurons, and decreased the number of bursts in 
the other 30% (25/84) ( Fig. 1). In each case the change in the level of bursts exceeded 10% of the control 
values, no cell was unaffected, and the effect lasted on average 5 min, thereafter returning to control 
levels. Each of these effects was found to be CB1-specific, as the effects were completely blocked during 
the subsequent co-administration of AM251 and AEA in a sub-set of 36 cells (22 increased the number of 
bursts in the presence of AEA alone and 14 decreased the number of bursts; Fig. 1).Those cells which 
elevated their burst firing in response to AEA ( Fig. 1a, upper histogram) did not change their overall 
firing rate ( Fig. 1a lower histogram) while those which showed a decrease in the number of bursts ( Fig. 
1b, upper histogram) showed a significant decrease in spontaneous firing ( Fig. 1b, lower histogram). 
However, in the control conditions these two groups were not significantly different (p > 0.05, Mann–
Whitney U test). The administration of AM251 alone (N = 42, Fig. 1c) or vehicle alone (N = 34, data not 
shown) had no significant effects (p > 0.05 vs. control, Wilcoxon signed-rank test). An example of the 
firing patterns of three simultaneously recorded individual cells is shown in the raster plots in Fig. 1d. The 
clear increase in bursting activity during AEA application is seen in the lower recordings (a 48% increase 
on average for these cells), with the development of an oscillatory pattern (see below). 
 
 
 
Fig. 1. Effect of AEA on the rate of bursting of dLGN neurons during spontaneous activity. (a, b) Upper figures: bar histograms 
represent the average number of bursts observed in the population during 5 min of spontaneous activity. The administration of AEA 
(0.5 mg/kg iv) had two distinct and different effects in our population of neurons: increasing (a, N = 59) or decreasing (b, N = 25) 
the rate of burst occurrence during spontaneous activity. ∗p < 0.05 vs. control, paired Student t-test. Further, these effects were 
abolished by the co-administration of AM251 (0.5 mg/kg iv) (a, N = 22; b, N = 14; p > 0.05 vs. control, paired Student t-test). Lower 
figures: bar histograms of the actual firing rates in spikes/s, divided into two groups according to the effect of AEA on the number 
of bursts fired (top row). Only the second group showed a significant change, a decrease in spontaneous activity (p < 0.05 vs. 
control, paired Student t-test). (c) Bar histogram representing the lack of effect of AM251 on the number of bursts when applied 
alone. (d) Representative spike raster plots for three different neurons recorded simultaneously, showing the activity during control 
condition (upper panel) and during the induction of burst firing by the administration of AEA (lower panel). All data are expressed 
as mean ± S.E.M. 
We found that the cells which increased the number of bursts during the administration of AEA also 
increased the percentage of spikes in bursts, number of spikes per burst and burst duration (Fig. 2a), while 
these parameters where not significantly affected in neurons whose burst responses were decreased by 
AEA (Fig. 2b). Similarly, co-administration of AM251 completely blocked these effects of AEA (Fig. 2). 
 
 
 
Fig. 2. Effect of AEA (0.5 mg/kg iv) on intrinsic bursts characteristics in dLGN neurons during spontaneous activity. Neurons that 
increased the number of bursts in the presence of AEA (a) also increased the percentage of spikes in bursts, the number of spikes per 
burst and burst duration. Neurons where AEA induced a decrease in the number of bursts (b) did not show any change in any of 
these parameters (a, N = 59; b, N = 25). ∗p < 0.05 vs. control, paired Student t-test. Further, the administration of the CB1 antagonist 
AM251 (0.5 mg/kg iv) to a subpopulation of cells totally blocked the AEA-mediated effects on intrinsic burst characteristics (a, 
N = 22; b, N = 14), p > 0.05 vs. their own control, paired Student t-test. Data expressed as mean ± S.E.M. 
AEA induces a delta-like oscillatory activity pattern in the dLGN 
We investigated the effect of AEA on the oscillatory activity pattern of our population of neurons finding 
that it induced a delta-like oscillation of 1.5 Hz in a significant majority of the cells tested (N = 59, 70%). 
This effect is illustrated in Fig. 3, which shows the autocorrelograms of six simultaneously recorded 
dLGN neurons in control condition (a) and during the administration of AEA (b), where all began to 
oscillate at delta-like frequencies. Interestingly, we found a positive correlation between the appearance 
of this AEA-mediated delta-like oscillation and the increase in burst firing previously described. The 
development of an oscillatory pattern is clear even by simple visual inspection in Fig. 1d, during AEA 
administration. Specifically, those neurons that had increased the number of bursts during the presence of 
AEA (59/84, see above) shifted into oscillation at ∼1.5 Hz ( Fig. 4a black line, Fig. 4c), while the pattern 
of those neurons that had decreased their burst firing (25/84) was not significantly altered ( Fig. 4b black 
line, Fig. 4c). Furthermore, it can be seen by comparing Fig. 4a and b that these two groups of neurons 
also differed in their oscillatory activity under control conditions, prior to drug administration. Those 
neurons that started to oscillate at delta-like frequencies in the presence of AEA were already oscillating 
at slow-like frequencies (0.5 Hz) in control conditions ( Fig. 4a solid gray line), while those neurons that 
did not change their oscillatory activity in the presence of AEA (25/84) did not oscillate at this frequency 
( Fig. 4b solid gray line). Fig. 4d shows an example of two simultaneously recorded cells, representing on 
the left a cell that showed a slow-like frequency in control conditions that switched to 1.5 Hz with the 
administration of AEA, while the cell shown on the right did not oscillate in control conditions or during 
drug application. These results suggest that the observed effects are not the consequence of a global 
change in state, as the two cells reported above were recorded simultaneously and yet had opposite 
responses to drug administration. 
 
 
 
Fig. 3. Autocorrelograms of six simultaneously recorded dLGN neurons during control condition (left) and presence of AEA 
(0.5 mg/kg iv, right). The administration of AEA induced an oscillatory activity at delta-like frequencies (1.5 Hz) in all the cells. 
 
 
 
 
Fig. 4. PSD graphs showing the effect of AEA on the oscillatory activity patterns of the neurons that increased (a) or decreased (b) 
their rate of bursting. (c) Bar histogram comparing the percentage of increase in the 1.5-Hz band vs. control, for the two populations. 
(d) The power spectrum analysis of two simultaneously recorded cells showing that the cell (left) previously oscillating changes the 
frequency under AEA influence, while the cell (right) that is not oscillating in control is not induced to do it by the application of the 
drug. ∗p < 0.05 vs. control, Wilcoxon signed-rank test. Data are expressed as mean ± S.E.M. 
Since we recorded multiple single units simultaneously, in groups ranging from four to eight cells, in 
several animals, the simplest way to view this data is as shown in Fig. 5, showing the entire set of 84 
cells. Here each bar represents the number of cells recorded simultaneously from a single eight electrode 
array, which was reinserted up to three times in each of the six animals. White bars indicate the number of 
simultaneously recorded cells which increased bursting and black ones those which decreased. The 
obvious scattering in some penetrations/animals, versus the complete single effect in others does not 
permit a clean suggestion of a single effect based upon the animals status at the time, rather there are 
multiple effects seen across populations of cells. Further, since these electrodes were stereotaxically 
placed vertically into the dLGN, there is also no obvious internal location effect or apparent laminar 
effect.  
 
 
 
Fig. 5. Each bar represents the number of cells recorded simultaneously in a single penetration (up to eight electrodes), the white 
portion indicates the number of cells which increased bursting, and the black portion those cells that decreased bursting after AEA 
application. While all cells recorded in animal 2 and almost all in animal 6 showed increased bursting in response to AEA, there was 
a much more mixed picture overall, and no suggestion of a physical or temporal pattern. 
Co-administration of AM251 to a subgroup of cells oscillating at 1.5 Hz as a result of AEA injection 
(N = 19) completely abolished the oscillation. This effect is exemplified in Fig. 6, which shows the 
activity of one of these cells during control condition (left), during the presence of AEA (middle) and co-
administration of AM251 (right). Further, administration of AM251 alone was without effect (N = 8, Fig. 
7a), as was injection of vehicle alone (N = 13, Fig. 7b). 
 
 
 
Fig. 6. Autocorrelograms of a single dLGN neuron during control (left), application of AEA (0.5 mg/kg iv, middle) and co-
administration of AEA and AM251 (0.5 mg/kg iv, right). The slow delta-like oscillation induced by the presence of AEA (middle) is 
totally blocked when the CB1 antagonist AM251 is co-applied (right).  
 
 
 
Fig. 7. Psd graphs averaging the effect of AM251 (a) and vehicle (b) when administered alone to a subgroup of cells where the 
presence of AEA induced the appearance of a 1.5-Hz oscillation. The population data are expressed as mean ± S.E.M. No 
significant effects were detected in any case (p > 0.05 vs. control, Wilcoxon signed-rank test). 
The delta-like thalamic oscillation induced by AEA administration was also seen at the level of the 
cerebral cortex. This is shown in Fig. 8, which shows an ECoG recorded from V1 during control 
conditions (a), presence of AEA (b) and recovery (c). AEA administration clearly reinforced the power of 
a previously weak delta-like oscillation around 2.0 Hz, while it totally suppressed the 0.5-Hz slow-like 
activity also present during control conditions. These effects were also seen at the population level, as 
shown in Fig. 8d and e, which illustrate the power of the slow-like (0–0.5 Hz) and delta-like (1–2 Hz) 
bands respectively, during control condition (left column), presence of AEA (middle column) and 
recovery (right column). While the delta-like oscillatory activity was significantly increased, the slow-like 
activity was decreased. 
 
 
 
Fig. 8.  The effects induced by AEA were also reflected at the ECoG level. A raw example of an ECoG is shown (upper traces) 
during control (a), administration of AEA (b) and recovery (c), along with the corresponding PSD analysis for each condition. In 
this example, AEA clearly increased the power of the oscillatory activity in the delta range while abolishing a slow-like oscillation 
present during control conditions. (Scale bars = 1 mV and 5 s). (d, e) show the mean data for the population (N = 11). ∗p < 0.01 vs. 
control, Friedman test with Bonferroni correction. 
  
Discussion 
Our data suggest that our pharmacological alteration of the endocannabinoid system during a 
physiological steady-state induces a significant shift in the firing pattern of thalamic cells. This activation 
of the CB1 receptor-mediated “network” results in a significant increase in burst firing in a majority of 
the cell population, including changes in burst duration and the number of spikes involved, all indicative 
of enhanced inhibition or withdrawal of an excitatory drive, resulting in hyperpolarization. However, we 
also found a smaller but significant proportion of cells which did not follow this pattern. These cells 
showed a small decrease in some elements of burst firing, but the other burst measures were unchanged. 
Interestingly, there was no overall shift in the basal firing rate of those cells which increased burst firing, 
but a significant decrease in those in which the number of bursts fired was reduced, which may again 
suggest increased inhibition or decreased excitation. However, it is known that the relationship between 
the degree of inhibition and the level of burstiness is complex, particularly in vivo ( Grieve et al., 2009). 
More interestingly, the firing pattern measured both at the single-cell level, and at the higher level, in 
terms of thalamocortical interactions revealed via the ECoG, have shown a shift in oscillatory patterned 
activity with a significant shift from frequencies below 1 Hz to a peak at 1.5 Hz in the delta range. 
Crucially, this only occurred in those cells which had shown an increase in burst firing. Moreover, cells 
which did not show this shift did not show a significant low-frequency oscillation in control conditions. 
These two response types were found intermingled in groups of cells recorded simultaneously (Fig. 5) 
indicating that our pharmacological intervention did not simply shift the thalamic “state”, rather one 
population of cells shifted to a burstier pattern with more 1.5-Hz activity, while a second population 
reduced spontaneous firing, with no major shift in oscillation. There was no evidence of specific thalamic 
locations or laminae showing distinct effects, the two seemed to be almost randomly distributed with no 
obvious groupings. Since we elected to examine only spontaneous activity in these cells, we have no 
further evidence to suggest division of these populations by physiological sub-type. 
The two main effects described here (increase of bursting activity and induction of delta-like 
oscillations) seem to be the consequence of the hyperpolarization of thalamic cells due to the activation of 
CB1 receptors. Indeed, the increase in burst firing in these cells is a landmark of a general hyperpolarized 
state in the dLGN (Sherman and Guillery, 2002) and is in agreement with the reported inhibitory effect of 
CB1 activation during visual stimulation in the dLGN of the rat (Dasilva et al., 2012). In addition, this 
assumption is supported by the fact that delta oscillations are characteristic of thalamocortical cells during 
deep non-REM (Rapid Eye Movement) sleep (Steriade et al., 1993), a state in which thalamocortical relay 
neurons are hyperpolarized (Steriade et al., 1993 and Steriade, 2004) and start to oscillate intrinsically at 
delta frequencies, due to the interplay of Ih and It currents ( Dossi et al., 1992). Interestingly, application 
of CB receptor antagonist, while completely reverted the effect, did not have a measurable effect when 
tested alone. Although this may suggest that CB mediated basal activity is absent due to our experimental 
conditions, similar results have been reported in awake rats ( Robbe et al., 2006). Our secondary 
population, although showing less bursting activity, did show a significant decrease in firing rate, which 
could also indicate a relative hyperpolarization, although not enough to reach a “bursting state”. However, 
in contrast to our previous study, we did not find any cells with spontaneous activity elevated by the 
activation of CB1 receptors, probably due to the use of a different anesthetic regime – chosen to allow a 
direct comparison with previous studies on thalamocortical oscillations ( Steriade et al., 1993) – and to 
the study design itself, which called for longer periods of recording in order to maximize the number of 
bursts recorded, such that small brief elevations might be averaged below significance. 
A simple explanation for exogenously applied endocannabinoids to induce a general hyperpolarization 
in the dLGN would be a dysfacilitation of dLGN neurons by reducing excitatory inputs. One of the main 
depolarizing afferents to the dLGN is the cholinergic input coming from the brainstem (Steriade, 2004). 
This has a significant role in the maintenance of arousal and shift from sleep to wake, hence an 
endocannabinoid-mediated inhibition of this input would effectively hyperpolarize the dLGN, increasing 
its bursting activity and inducing it to oscillate at delta-like frequencies. Actually, this mechanism has 
already been proposed to underlie the AEA-mediated induction of sleep (REM and non-REM) in rats 
(Murillo-Rodríguez et al., 1998 and Murillo-Rodríguez et al., 2001) and is part of the normal process 
during non-REM sleep, where there is a progressive decrease in the firing rate of cholinergic brainstem 
thalamic inputs (Steriade et al., 1993). Thus, our data support previous behavioral studies in rats that have 
reported a sleep-inducing effect of endocannabinoids (Santucci et al., 1996, Murillo-Rodríguez et al., 
1998 and Murillo-Rodríguez et al., 2001). 
Another mechanism that could explain the hyperpolarizing effect of endocannabinoids in the dLGN, 
potentially acting in concert with the above, is the reduction of the cortical feedback to the thalamus. The 
dLGN receives significant feedback connections from the cortex (Sefton et al., 1981 and Garey et al., 
1991) which activate group I mGluR1a (McCormick and von Krosigk, 1992). These feedback 
connections are used to transmit slow oscillatory activity to the thalamus which is generated in the cortex 
during non-REM sleep (Steriade et al., 1993 and Steriade, 2003) in an mGluR1a activation-dependent 
manner (Hughes et al., 2002).The disruption of these connections has a hyperpolarizing effect on relay 
cells (Kalil and Chase, 1970 and Waleszczyk et al., 2005), maybe mediated by the action of 
endocannabinoids as Sun et al. (2011) have demonstrated in the somatosensory system, showing that 
these compounds decrease the strength of thalamocortical synapses. Reviewing our data, in which the 
cells that shifted to delta-like oscillation during CB1 receptor activation were those that were already 
oscillating in control conditions at very low frequencies, we submit that this pattern could also follow a 
local hyperpolarization of the dLGN by withdrawal or reduction of the descending excitatory drive from 
the cortex, disrupting the slow oscillatory activity generated in the cortex and transmitted to the thalamus. 
Actually, it is known that slow oscillations are absent in the thalamus of decorticated animals (Timofeev 
and Steriade, 1996) and our data also show, at the ECoG level, a distinct suppression of the slow 
oscillatory activity, something that has been reported to occur when intracortical connections are 
disrupted (Amzica and Steriade, 1995). Thus, it could be that in our case the cannabinoid agonist, which 
was administered intravenously to act upon endocannabinoid receptors, was actively disrupting either the 
intrinsic activity of the cortex, as has been previously reported in somatosensory and prefrontal areas 
(Auclair et al., 2000 and Fortin and Levine, 2007), or corticofugal glutamatergic neurotransmission as 
shown recently in basal ganglia/cortex interactions (Sales-Carbonell et al., 2013). 
Within the thalamus, the control of the level of arousal is not simply linked to the level of excitatory 
inputs (brainstem or cortical) but must include the known inhibitory inputs, both from local, intrinsic 
GABAergic interneurons and the nearby GABAergic cells of the TRN, a network of interconnected 
inhibitory cells under the influence of the cortex that receive feedforward input from the thalamic cells 
they inhibit (Sherman and Guillery, 2002), a nucleus that is predominantly active during sleep-like states 
and that becomes depressed during conscious awareness. However the actual effect of the 
endocannabinoid system on the output from the TRN is puzzling since it could decrease the cortical input 
to the TRN reducing the inhibitory drive to relay cells (as shown in the somatosensory system by Sun et 
al., 2011), but it could also decrease lateral inhibitory connections inside the TRN potentially increasing 
the GABAergic input to relay cells (Sun et al., 2011). 
Furthermore, it is well known that the effect of ACh on GABAergic cells, both intrinsic to the dLGN 
and resident in the TRN, is normally inhibitory (Godfraind, 1978 and McCormick and Pape, 1988). So, 
an endocannabinoid-mediated reduction in cholinergic drive could effectively enhance inhibition or alter 
the balance of interactions between inhibitory cells in unknown and complex ways. Furthermore, Sales-
Carbonell et al. (2013) have reported increased oscillatory activity in somatosensory cortex, which they 
ascribe to an increased inhibitory input to the thalamus, in their case arising from substantia nigra pars 
reticulata (SNr), indicating that there may be a general link between cannabinoid control of 
thalamocortical oscillations which can be utilized by appropriately located inhibitory drives. In the case of 
the LGN, this would also be reflected in a measureable change in bursting activity 
We can suggest several routes by which endocannainoids can alter the function of thalamic cells, both 
in simple terms of their firing rates and in terms of more complex oscillatory and bursting activities, but 
we cannot ascribe a single mechanism that is more likely than any another, which suggests that the 
likeliest is a combination of withdrawal of excitation, enhanced inhibition, and interactions within and 
between circuit elements. In future, new experiments –perhaps combining intracellular recordings and 
local drug application– could be used to further clarify the actual underlying mechanisms. However, the 
current study reveals the activation of thalamic CB1 receptors as a significant element involved in the 
regulation of thalamic rhythmicity, which has been postulated as a key element of sleep. Thus, these 
results also help us to understand the mechanisms mediating the known effect of cannabis as a sleep-
inducing agent. 
Conclusion 
The current study reveals for the first time that the activation of thalamic CB1 receptors by AEA is a 
significant element in regulating burst firing and oscillatory activity, two phenomena closely related to the 
transition between wake and sleep and the level of vigilance. We suggest that the endocannabinoid 
system is involved in regulating the level of alertness, including actions intrinsic to the sleep–wake cycle. 
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